Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Operating Margin (2016 - 2025)

Historic Operating Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 4.92%.

  • Corcept Therapeutics' Operating Margin fell 206100.0% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 139600.0%. This contributed to the annual value of 20.29% for FY2024, which is 19500.0% down from last year.
  • Per Corcept Therapeutics' latest filing, its Operating Margin stood at 4.92% for Q3 2025, which was down 206100.0% from 13.72% recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Operating Margin high stood at 37.69% for Q3 2021, and its period low was 2.17% during Q1 2025.
  • In the last 5 years, Corcept Therapeutics' Operating Margin had a median value of 24.72% in 2021 and averaged 22.97%.
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 90600bps in 2021, then plummeted by -206100bps in 2025.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Operating Margin stood at 37.1% in 2021, then plummeted by -41bps to 21.83% in 2022, then rose by 7bps to 23.39% in 2023, then plummeted by -41bps to 13.89% in 2024, then crashed by -65bps to 4.92% in 2025.
  • Its Operating Margin stands at 4.92% for Q3 2025, versus 13.72% for Q2 2025 and 2.17% for Q1 2025.